<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html
PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
"DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
    <link rel="stylesheet" type="text/css" href="css/style-vis.css"/>
    <script type="text/javascript" src="js/head.js"></script>
    <title> View prodigy relations</title>
</head>

<body>
    <!-- Start BRAT (always static) -->
    <script type="text/javascript">
        var bratLocation = 'brat-v1.3_Crunchy_Frog';
        head.js(
        // External libraries
        bratLocation + '/client/lib/jquery.min.js',
        bratLocation + '/client/lib/jquery.svg.min.js',
        bratLocation + '/client/lib/jquery.svgdom.min.js',
        // brat helper modules
        bratLocation + '/client/src/configuration.js',
        bratLocation + '/client/src/util.js',
        bratLocation + '/client/src/annotation_log.js',
        bratLocation + '/client/lib/webfont.js',
        // brat modules
        bratLocation + '/client/src/dispatcher.js',
        bratLocation + '/client/src/url_monitor.js',
        bratLocation + '/client/src/visualizer.js'
        );
        var webFontURLs = [
            bratLocation + '/static/fonts/Astloch-Bold.ttf',
            bratLocation + '/static/fonts/PT_Sans-Caption-Web-Regular.ttf',
            bratLocation + '/static/fonts/Liberation_Sans-Regular.ttf'
        ];
    
    </script>

<div id="embedding-0" style="margin:50px"><p> Sentence#: 0
Task hash: -1252878258</p></div><div id="embedding-1" style="margin:50px"><p> Sentence#: 1
Task hash: -1032738347</p></div><div id="embedding-2" style="margin:50px"><p> Sentence#: 2
Task hash: -11365038</p></div><div id="embedding-3" style="margin:50px"><p> Sentence#: 3
Task hash: -315724013</p></div><div id="embedding-4" style="margin:50px"><p> Sentence#: 4
Task hash: -130849898</p></div><div id="embedding-5" style="margin:50px"><p> Sentence#: 5
Task hash: -2035778806</p></div><div id="embedding-6" style="margin:50px"><p> Sentence#: 6
Task hash: -489699072</p></div><div id="embedding-7" style="margin:50px"><p> Sentence#: 7
Task hash: -501760621</p></div><div id="embedding-8" style="margin:50px"><p> Sentence#: 8
Task hash: -1609218252</p></div><div id="embedding-9" style="margin:50px"><p> Sentence#: 9
Task hash: 169340965</p></div><script type="text/javascript"> head.ready(function() { 
    Util.embed(
    'embedding-0',
    collData,
    {
    text: "These results showed that the absorption rate constant (ka), elimination rate constant (ke), time to peak serum concentration (tmax), elimination half-life (t1/2), apparent volume of distribution (Vd/F), total body clearance (CL) and area under the serum concentration-time curve (AUC) were significantly different in infants under 6 months from those in children over 3 years (p less than 0.05), except for the peak serum concentration (Cmax) and lag time from administration to the first appearance of drug in the serum (tlag) [p greater than 0.05].",
    entities: [],
    relations: []
    },
    webFontURLs, 
    );
     
    Util.embed(
    'embedding-1',
    collData,
    {
    text: "The T1/2 ranged from: XA-a, 14.61 days (10 mg/kg, females) to 17.23 days (0.1 mg/kg, males); XA-b, 13.40 days (1 mg/kg, females) to 15.82 days (0.1 mg/kg, males); XA-c, 12.36 days (1 mg/kg, females) to 16.17 days (0.1 mg/kg, males).",
    entities: [['T0', 'PK', [[4, 8]]], ['T1', 'VALUE', [[28, 33]]], ['T2', 'VALUE', [[62, 67]]], ['T3', 'VALUE', [[99, 104]]], ['T4', 'VALUE', [[132, 137]]], ['T5', 'VALUE', [[169, 174]]], ['T6', 'VALUE', [[202, 207]]], ['T7', 'UNITS', [[34, 38]]], ['T8', 'UNITS', [[68, 72]]], ['T9', 'UNITS', [[105, 109]]], ['T10', 'UNITS', [[175, 179]]], ['T11', 'UNITS', [[208, 212]]], ['T12', 'UNITS', [[138, 142]]]],
    relations: [['R0', 'C_VAL', [['Entity', 'T0'], ['C_VAL', 'T1']]], ['R1', 'C_VAL', [['Entity', 'T0'], ['C_VAL', 'T2']]], ['R2', 'C_VAL', [['Entity', 'T0'], ['C_VAL', 'T3']]], ['R3', 'C_VAL', [['Entity', 'T0'], ['C_VAL', 'T4']]], ['R4', 'C_VAL', [['Entity', 'T0'], ['C_VAL', 'T5']]], ['R5', 'C_VAL', [['Entity', 'T0'], ['C_VAL', 'T6']]], ['R6', 'RELATED', [['Entity', 'T7'], ['RELATED', 'T1']]], ['R7', 'RELATED', [['Entity', 'T8'], ['RELATED', 'T2']]], ['R8', 'RELATED', [['Entity', 'T9'], ['RELATED', 'T3']]], ['R9', 'RELATED', [['Entity', 'T10'], ['RELATED', 'T5']]], ['R10', 'RELATED', [['Entity', 'T11'], ['RELATED', 'T6']]], ['R11', 'RELATED', [['Entity', 'T12'], ['RELATED', 'T4']]]]
    },
    webFontURLs, 
    );
     
    Util.embed(
    'embedding-2',
    collData,
    {
    text: "The predicted concentrations were used to compute the AUC from 0 to 60 days (AUC0–60) and Cmax values for the clinically recommended 300-mg dose.",
    entities: [],
    relations: []
    },
    webFontURLs, 
    );
     
    Util.embed(
    'embedding-3',
    collData,
    {
    text: "However, a subgroup comparison of drug formulations showed that, irrespective of dosing frequency, pediatric subjects receiving lamivudine as tablets were more than twice as likely to achieve virologic suppression compared with those receiving oral solution (adjusted odds ratio, 2.55; 95% confidence interval (CI), 0.89–6.39; P = 0.08).3 A pharmacokinetic (PK) substudy of ARROW conducted in children aged 1.8–4.0 years receiving the combination of lamivudine, abacavir, and zidovudine showed that the relative bioavailability of lamivudine solution was 37% lower than that of a scored adult‐tablet formulation.4 In contrast with the pediatric findings, an earlier relative bioavailability study in adults demonstrated that lamivudine solution provided equivalent exposures to lamivudine tablets and capsules when both the test and reference formulations were administered alone.5 Additionally, two relative bioavailability studies of pediatric‐strength, three‐drug, fixed‐dose combination tablet formulations that were conducted in children (aged 0.5–12 years) showed that lamivudine solution given in combination with either stavudine/nevirapine or zidovudine/nevirapine liquid formulations had 29% or 44% lower lamivudine exposures than lamivudine administered as part of a three‐drug tablet,6, 7 despite these three‐drug tablet formulations having been shown to be equivalent to solutions in adult relative bioavailability studies.8, 9 Unlike studies in adults, the pediatric relative bioavailability studies were conducted in children being treated for HIV‐1 with lamivudine in combination with one or more antiretroviral drugs.",
    entities: [],
    relations: []
    },
    webFontURLs, 
    );
     
    Util.embed(
    'embedding-4',
    collData,
    {
    text: "Moment analysis gave average +- SD mean residence times (MRT) of 4.98 +- 0.75 and 5.86 +- 0.77 hours after intravenous and intramuscular administration, respectively.",
    entities: [['T0', 'PK', [[40, 61]]], ['T1', 'VALUE', [[65, 69]]], ['T2', 'VALUE', [[82, 86]]], ['T3', 'VALUE', [[73, 77]]], ['T4', 'UNITS', [[95, 100]]], ['T5', 'VALUE', [[90, 94]]]],
    relations: [['R0', 'C_VAL', [['Entity', 'T0'], ['C_VAL', 'T1']]], ['R1', 'C_VAL', [['Entity', 'T0'], ['C_VAL', 'T2']]], ['R2', 'D_VAL', [['Entity', 'T3'], ['D_VAL', 'T1']]], ['R3', 'RELATED', [['Entity', 'T4'], ['RELATED', 'T3']]], ['R4', 'D_VAL', [['Entity', 'T5'], ['D_VAL', 'T2']]], ['R5', 'RELATED', [['Entity', 'T4'], ['RELATED', 'T5']]], ['R6', 'RELATED', [['Entity', 'T4'], ['RELATED', 'T2']]], ['R7', 'RELATED', [['Entity', 'T4'], ['RELATED', 'T1']]]]
    },
    webFontURLs, 
    );
     
    Util.embed(
    'embedding-5',
    collData,
    {
    text: "The 90% confidence interval analysis for the decrease in urine volume and increase in urine osmolality demonstrated that crushed and chewed tablets, and oral solution treatments were equivalent to whole tablet treatment in the area under curve from time 0 to the last sampling time point and maximum drug effect.",
    entities: [],
    relations: []
    },
    webFontURLs, 
    );
     
    Util.embed(
    'embedding-6',
    collData,
    {
    text: "The effects of juice E on S-warfarin AUC0–∞, Cl/F, and terminal t1/2 were more varied; relative to water, the difference ranged from −34% to 40% (Figure 4A), −29% to 52%, and −40% to 38% (Figure 4B), respectively.",
    entities: [],
    relations: []
    },
    webFontURLs, 
    );
     
    Util.embed(
    'embedding-7',
    collData,
    {
    text: "There was not a significant difference (p > 0.05) in AUC (48.59 +- 8.52 vs. 49.9 +- 9.93), Cmax (7.73 +- 2.6 vs. 6.6 +- 2.0), and tmax (1.1 +- 0.6 vs. 1.6 +- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",
    entities: [['T0', 'PK', [[53, 56]]], ['T1', 'VALUE', [[58, 63]]], ['T2', 'VALUE', [[76, 80]]], ['T3', 'PK', [[91, 95]]], ['T4', 'VALUE', [[97, 101]]], ['T5', 'VALUE', [[113, 116]]], ['T6', 'PK', [[130, 134]]], ['T7', 'VALUE', [[136, 139]]], ['T8', 'VALUE', [[151, 154]]], ['T9', 'VALUE', [[67, 71]]], ['T10', 'VALUE', [[84, 88]]], ['T11', 'VALUE', [[105, 108]]], ['T12', 'VALUE', [[120, 123]]], ['T13', 'VALUE', [[143, 146]]], ['T14', 'VALUE', [[158, 161]]]],
    relations: [['R0', 'C_VAL', [['Entity', 'T0'], ['C_VAL', 'T1']]], ['R1', 'C_VAL', [['Entity', 'T0'], ['C_VAL', 'T2']]], ['R2', 'C_VAL', [['Entity', 'T3'], ['C_VAL', 'T4']]], ['R3', 'C_VAL', [['Entity', 'T3'], ['C_VAL', 'T5']]], ['R4', 'C_VAL', [['Entity', 'T6'], ['C_VAL', 'T7']]], ['R5', 'C_VAL', [['Entity', 'T6'], ['C_VAL', 'T8']]], ['R6', 'D_VAL', [['Entity', 'T9'], ['D_VAL', 'T1']]], ['R7', 'D_VAL', [['Entity', 'T10'], ['D_VAL', 'T2']]], ['R8', 'D_VAL', [['Entity', 'T11'], ['D_VAL', 'T4']]], ['R9', 'D_VAL', [['Entity', 'T12'], ['D_VAL', 'T5']]], ['R10', 'D_VAL', [['Entity', 'T13'], ['D_VAL', 'T7']]], ['R11', 'D_VAL', [['Entity', 'T14'], ['D_VAL', 'T8']]]]
    },
    webFontURLs, 
    );
     
    Util.embed(
    'embedding-8',
    collData,
    {
    text: "Consistent with the parent drug of Enasidenib, metrics of the rate of production, as reflected by Cmax and the extent of production, as reflected by AUC0‐inf and AUC0‐t were either higher in Japanese subjects as compared to that in Caucasian subjects from 50 mg and 300 mg treatment cohorts, or lower in Japanese subjects as compared to that in Caucasian subjects from 100 mg treatment cohort (data not shown).",
    entities: [],
    relations: []
    },
    webFontURLs, 
    );
     
    Util.embed(
    'embedding-9',
    collData,
    {
    text: "The success rate was 99.3%, and the parameter estimates and SD of the final model were consistent with those of the bootstrap, which suggested good robustness and stability of the final model.",
    entities: [],
    relations: []
    },
    webFontURLs, 
    );
    }); 
var collData = 
{
    entity_types: [
    {type: 'PK',labels : ['PK', 'PK'], bgColor: '#ffa9b8',borderColor: 'darken'},
    {type: 'VALUE', labels : ['VALUE', 'V'], bgColor: '#d1caff', borderColor: 'darken'},
    {type: 'UNITS', labels : ['UNITS', 'U'],bgColor: '#00ffff',borderColor: 'darken'},
    {type: 'TYPE_MEAS',labels : ['TYPE_MEAS', 'T'],bgColor: '#ffa973',borderColor: 'darken'},
    {type: 'COMPARE', labels : ['COMPARE', 'COM'], bgColor: '#9effd6',borderColor: 'darken'},
    {type: 'RANGE', labels : ['RANGE', 'R'], bgColor: '#66f542',borderColor: 'darken'}       
    ],
    relation_types: [
    { type: 'C_VAL', labels: ['C_VAL', 'C'], color : 'blue'},
    { type: 'D_VAL', labels   : ['D_VAL', 'D'], color: '#ff8c00'},
    { type: 'RELATED', labels: ['RELATED', 'R'], color: '#32cd32',}
    ]
};
</script>
</body>
</html>
